Vera Therapeutics, Inc. announced on June 7, 2024, the board of directors (the board) of Vera the company appointed Christy Oliger to the board, effective immediately. Ms. Oliger will serve as a Class III Director, with an initial term expiring at the company's 2027 Annual Meeting of Stockholders. Ms. Oliger was also appointed to serve on the nominating and corporate governance committee of the Board (the nominating committee), effective as of her appointment to the board.

Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. Ms. Oliger currently serves on multiple public company boards, including Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics. She previously served on the boards of Sierra Oncology until its acquisition by GSK in 2022, Reata Pharmaceuticals until its acquisition by Biogen in 2023, and RayzeBio until its acquisition by Bristol Myers Squibb in 2024.

In her most recent operational role, Ms. Oliger served as Genentechs Senior Vice President, Oncology Business Unit Head from 2017 to 2020. During her tenure at Genentech, she held senior commercial leadership roles across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology, and immunology. In addition, while at Genentech Ms. Oliger held senior R&D roles, including leading the Roche global portfolio management function.

Ms. Oliger holds a Bachelor of Arts in Economics from the University of California at Santa Barbara.